An association sensitive to analysis design needs that uncertainty preserved.
Among patients treated for depression after breast-cancer diagnosis, the initial one-to-one matched comparison did not show a clear dementia difference. More detailed exposure analyses and a one-to-four matched analysis produced different associations, including a higher dementia incidence in the combination-treatment group.
This was observational evidence. Diagnostic coding, underlying symptoms, exposure definitions and residual confounding can affect results. Higher dose or longer use associations do not by themselves prove that benzodiazepines caused dementia.
Describe the sensitivity of the conclusion rather than selecting only the strongest estimate. The paper cannot establish the cause of an individual cognitive decline or a personal probability from a group hazard ratio. Clinical history and alternative neurological, oncological and treatment-related explanations remain necessary.
Source: PMC12394756, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Persistent Sedation After Naloxone Can Occur With Illicit-Benzodiazepine Co-Exposure.